Group 1 - The core point of the article is that Dingdang Health has been actively repurchasing its shares, with a total of 5.21 million shares bought back on January 16 at prices ranging from 1.050 to 1.240 HKD, amounting to 5.84 million HKD [1] - Since November 25, 2025, the company has conducted share repurchases for 36 consecutive days, totaling 23.99 million shares and a cumulative repurchase amount of 26.66 million HKD [1] - The stock has seen a cumulative increase of 5.83% during the repurchase period [1] Group 2 - In 2026, the company has completed 11 repurchase transactions, acquiring a total of 14.73 million shares for a total amount of 16.72 million HKD [1] - The detailed repurchase data shows varying prices and amounts, with the highest repurchase price recorded at 1.240 HKD and the lowest at 1.050 HKD on January 16 [1] - The stock closed at 1.090 HKD on the same day, reflecting an 11.38% decline with a total trading volume of 17.43 million HKD [1]

天立国际控股(01773)发布公告，于2026年1月16日，该公司斥资56.6万港元回购20万股。 ...

Group 1 - The company, Heartbeat Company (02400), announced a share buyback on January 16, 2026, spending HKD 1.9731 million to repurchase 23,200 shares at a price range of HKD 83.45 to 86.15 per share [1] - On the same date, the company issued a total of 33,000 ordinary shares due to eligible participants exercising stock options under the share option scheme adopted on June 25, 2021 [1]

智通财经APP讯，健康之路(02587)发布公告，于2026年1月16日，该公司斥资56.14万港元回购11.2万 股。 ...

Core Viewpoint - Beike-W (02423) announced a share repurchase plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Repurchase Details - The company plans to repurchase approximately 598,900 shares at a cost of about $3.5 million [1] - The repurchase price per share is set between $5.79 and $5.90 [1]

Investment Rating - The report does not explicitly provide an investment rating for the company [5]. Core Insights - The report aligns with the views of CITIC Lyon Research, indicating that Kajima Corporation's new orders will shift towards more profitable infrastructure, nuclear power plants, and factory projects, enhancing the company's profitability [5]. - The data center business is expected to improve construction profit margins, and a decrease in U.S. interest rates could lead to increased capital gains for the company [5][7]. Summary by Relevant Sections New Orders and Profitability - Kajima Corporation is predicted to secure more profitable projects, particularly in nuclear power plants, semiconductor factories, and office buildings, with the restart of nuclear power plants driving demand for data center construction in the coming years [6]. Capital Gains Potential - As of the first half of the fiscal year 2026, the company holds real estate assets valued at 1 trillion 3.3 billion yen, with 520 billion yen in Japan and 810 billion yen overseas (50% of which is in the U.S.). A decrease in U.S. interest rates could allow the company to realize capital gains through the sale of logistics assets [7]. Share Buyback and Cross-Shareholdings - The company is expected to implement a 30 billion yen stock buyback, funded by the reduction of cross-shareholdings, with proceeds from this reduction anticipated to be used for buybacks in fiscal year 2027 [8]. Catalysts - Potential catalysts for the company include: 1) Disclosure of factory orders; 2) Improvement in construction profit margins; 3) Increased capital gains from asset sales [9]. Company Overview - Kajima Corporation is one of Japan's four major general construction companies, historically closely linked with Mitsui Fudosan. The company's business primarily focuses on private sector construction projects, a trend expected to continue, with nearly three-quarters of orders coming from Japan's domestic private sector over the past decade. Its overseas real estate business, primarily focused on U.S. logistics development, has become another pillar [11].

公司已收到农业银行菏泽牡丹支行出具的贷款承诺函，该行承诺对公司发放贷款额度为1亿元，贷款期 限3年，贷款年利率2%；仅用于公司在该承诺函出具日之后进行的公司股票回购。 人民财讯1月16日电，步长制药（603858）1月16日公告，拟0.6亿元—1.2亿元回购公司股份，用于实施 股权激励、员工持股计划、转换上市公司发行的可转换为股票的公司债券，回购价格不超过23.98元/ 股。 ...

证券日报网讯1月15日，蓝思科技（300433）在互动平台回答投资者提问时表示，公司自2025年7月9日 首次回购以来，已多次实施回购，累计回购约740万股，近期公司股价也持续走强并创下历史新高。公 司将在董事会批准的额度内持续回购，继续持续维护股价稳定增长，保护好中小投资者利益。 ...

来源：第一财经 随着利润激增以及资本监管政策放宽，华尔街银行向股东返还了创纪录的资金，这显示出高管们对加大 股票回购力度充满信心。2025年，美国六大银行在股息和回购方面的支出超过1400亿美元，打破了特朗 普首个任期内于2019年创下的纪录。其中，摩根大通回购了超过300亿美元的股票，创下华尔街银行的 最高纪录，规模是两年前的三倍多。在特朗普的第二个任期内，随着监管机构寻求放宽关键资本要求， 银行在将利润返还给股东方面变得更加从容。去年6月，美联储采取行动，降低了控股公司在"增强补充 杠杆率"规则下的资本要求，该规则适用于摩根大通、美国银行和高盛集团等大型银行。银行预计这种 势头在今年仍将持续。高盛首席执行官所罗门周四表示，该行在回购股票时将"保持动力"。 ...

本文源自：金融界AI电报 随着利润激增以及资本监管政策放宽，华尔街银行向股东返还了创纪录的资金，这显示出高管们对加大 股票回购力度充满信心。2025年，美国六大银行在股息和回购方面的支出超过1400亿美元，打破了特朗 普首个任期内于2019年创下的纪录。 ...